Greater Cannabis Company (GCAN) Total Debt (2016 - 2023)
Greater Cannabis Company's (GCAN) quarterly Total Debt came in at $36000.0 in Q3 2023, down 90.89% year-on-year from $395000.0 in Q3 2022, and down 86.15% quarter-over-quarter from $260000.0 in Q4 2022.
Greater Cannabis Company (GCAN) Total Debt (2016 - 2023) Analysis & Trends
Greater Cannabis Company's Total Debt history runs 8 years deep, the most recent figure standing at $36000.0 for Q3 2023.
- On a quarterly basis, Total Debt fell 90.89% year-over-year to $36000.0 in Q3 2023; TTM through Sep 2023 was $36000.0, a 90.89% decrease from a year earlier, with the FY2022 full-year figure at $260000.0, changed 0.0% from the prior year.
- Total Debt slipped to $36000.0 in Q3 2023 per GCAN's latest filing, from $260000.0 in the prior quarter.
- Across five years, Total Debt topped out at $585212.0 in Q4 2020 and bottomed at $36000.0 in Q3 2023.
- The 5-year median for Total Debt is $282500.0 (2021), against an average of $328279.1.
- Across the five-year window, Total Debt surged 2023.32% in 2019 and tumbled 90.89% in 2023, its largest moves.
- Year by year, Total Debt stood at $260000.0 in 2019, then jumped by 125.08% to $585212.0 in 2020, then plunged by 55.57% to $260000.0 in 2021, then changed by 0.0% to $260000.0 in 2022, then slumped by 86.15% to $36000.0 in 2023.
- Per Business Quant, the three latest GCAN Total Debt figures stand at $36000.0 (Q3 2023), $260000.0 (Q4 2022), and $395000.0 (Q3 2022).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 11.45 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.63 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 28.76 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 7.15 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.34 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.81 Bn |
| 10 | Greater Cannabis Company | 292,929.85 | 292,929.85 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 36,000.00 |
| Dec 31, 2022 | 260,000.00 |
| Sep 30, 2022 | 395,000.00 |
| Jun 30, 2022 | 285,000.00 |
| Mar 31, 2022 | 260,000.00 |
| Dec 31, 2021 | 260,000.00 |
| Sep 30, 2021 | 571,050.00 |
| Jun 30, 2021 | 282,500.00 |
| Mar 31, 2021 | 282,500.00 |
| Dec 31, 2020 | 585,212.00 |
| Sep 30, 2020 | 571,050.00 |
| Jun 30, 2020 | 327,082.00 |
| Mar 31, 2020 | 425,350.00 |
| Dec 31, 2019 | 260,000.00 |
| Sep 30, 2019 | 260,000.00 |
| Jun 30, 2019 | 260,000.00 |
| Mar 31, 2019 | 260,000.00 |
| Dec 31, 2018 | 260,000.00 |
| Sep 30, 2018 | 260,000.00 |
| Jun 30, 2018 | 19,299.00 |